| 08-Mar-14 01:04PM | SAREPTA THERAPEUTICS, INC. Financials EDGAR Online Financials |
| 07-Mar-14 06:49PM | SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline -- SRPT GlobeNewswire |
| 06:17PM | The Nasdaq's 5 Most Hated Stocks at Motley Fool |
| 04-Mar-14 06:32PM | Why Sarepta Therapeutics Inc. Might Have a Fighting Chance at Motley Fool |
| 06:29PM | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT PR Newswire |
| 09:57AM | On Sarepta's 2013 Results And Upcoming Events at Seeking Alpha |
| 03-Mar-14 04:59PM | SAREPTA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report EDGAR Online |
| 01:21PM | Sarepta Therapeutics: Tale of a Biotech Rollercoaster at Motley Fool |
| 28-Feb-14 03:02PM | SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Sarepta Therapeutics, Inc. and Certain Officers - SRPT PR Newswire |
| 27-Feb-14 04:13PM | Sarepta Therapeutics' CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 12:46PM | Sarepta price target raised to $34 from $21 at Stifel at theflyonthewall.com |
| 12:15PM | Sarepta Therapeutics Q4 Loss More Than Triples on a Doubling in Expenses at Motley Fool |
| 08:00AM | Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today CCBN |
| 07:17AM | Sarepta sees FY14 loss from operations $110M-$120M at theflyonthewall.com |
| 07:08AM | SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online |
| 07:07AM | Q4 2013 Sarepta Therapeutics Inc Earnings Release - Before Market Open CCBN |
| 07:00AM | Sarepta Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Recent Corporate Developments Business Wire |
| 26-Feb-14 05:52AM | Sarepta (SRPT) Enters Overbought Territory Zacks |
| 25-Feb-14 01:05PM | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT GlobeNewswire |
| 24-Feb-14 10:39AM | The 10 Most Heavily Shorted Bio-Pharma Stocks at TheStreet +7.63% |
| 05:14AM | Trades are optimistic on Sarepta optionMONSTER |
| 21-Feb-14 10:00AM | Chen Lin's Perfect Biotech Market Prescription: Buy Low, Sell High at Seeking Alpha |
| 20-Feb-14 04:05PM | Sarepta Therapeutics to Present Company Overview at the Cowen and Company 34th Annual Healthcare Conference Business Wire |
| 12:01AM | JPMorgan Dad Turns Biotech CEO in Quest to Save His Son Bloomberg |
| 12:01AM | JPMorgan Dad Starts Biotech in Muscular Dystrophy Quest at Bloomberg |
| 17-Feb-14 03:37PM | 3 Biotech Stocks to Avoid: Amarin, Dendreon, and Prosensa at Motley Fool |
| 14-Feb-14 05:11PM | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- SRPT GlobeNewswire |
| 13-Feb-14 08:30AM | Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2013 Financial Results and Corporate Update on February 27, 2014 Business Wire |
| 10-Feb-14 08:30AM | Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate Business Wire |
| 07-Feb-14 02:05PM | Do Away With The Pill-A-Day Biotech Model: Steve Brozak at Seeking Alpha +5.12% |
| 06-Feb-14 01:16PM | Advocates set to meet with Congress on Sarepta DMD drug at theflyonthewall.com |
| 05-Feb-14 02:03PM | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT Marketwired +9.45% |
| 02:03PM | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT Marketwire |
| 08:30AM | Sarepta Therapeutics Announces Eteplirsen Demonstrates Stability on Pulmonary Function Tests through 120 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy Business Wire |
| 04-Feb-14 06:32PM | Companies Limp Towards a Duchenne Treatment Is There Hope of a Finish Line? at Motley Fool |
| 05:59PM | Attention Sarepta Therapeutics, Inc. Investors: Sarepta Misled Investors According to a Recently Filed Class Action PR Newswire |
| 31-Jan-14 05:41PM | Morgan & Morgan Announces That a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. -- SRPT GlobeNewswire |
| 05:41PM | Morgan & Morgan Announces That a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. -- SRPT |
| 30-Jan-14 03:42PM | SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Sarepta Therapeutics, Inc. and Certain Officers -- SRPT GlobeNewswire |
| 03:42PM | SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Sarepta Therapeutics, Inc. and Certain Officers -- SRPT |
| 02:39PM | Wolf Haldenstein Announces Investigation of Sarepta Therapeutics, Inc., Business Wire |
| 02:39PM | Wolf Haldenstein Announces Investigation of Sarepta Therapeutics, Inc., |
| 28-Jan-14 03:30PM | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT GlobeNewswire |
| 03:30PM | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT |
| 27-Jan-14 06:19PM | INVESTOR ALERT: Federman & Sherwood Files First Securities Class Action Lawsuit Against Sarepta Therapeutics, Inc. Marketwired |
| 06:19PM | INVESTOR ALERT: Federman & Sherwood Files First Securities Class Action Lawsuit Against Sarepta Therapeutics, Inc. Marketwire |
| 06:19PM | INVESTOR ALERT: Federman & Sherwood Files First Securities Class Action Lawsuit Against Sarepta Therapeutics, Inc. |
| 06:24AM | Sarepta downgraded to Market Perform from Outperform at JMP Securities theflyonthewall.com |
| 06:24AM | Sarepta downgraded to Market Perform from Outperform at JMP Securities |
| 24-Jan-14 12:18AM | Intercept Pharmaceticals & Chelsea Therapeutics: Which is Best? at Motley Fool -7.69% |
| 12:18AM | Intercept Pharmaceticals & Chelsea Therapeutics: Which is Best? |
| 23-Jan-14 07:25AM | The Zacks Analyst Blog Highlights: Celgene, Jazz, Sarepta, Alnylam and Regeneron Zacks |
| 07:25AM | The Zacks Analyst Blog Highlights: Celgene, Jazz, Sarepta, Alnylam and Regeneron |
| 05:56AM | How Sarepta Trading Will Evolve at Seeking Alpha |
| 05:56AM | How Sarepta Trading Will Evolve |
| 22-Jan-14 12:48PM | Professional Investor Explains His 2 Largest Healthcare Holdings at Seeking Alpha |
| 12:48PM | Professional Investor Explains His 2 Largest Healthcare Holdings |
| 09:50AM | Professional Investor Explains His 2 Largest Healthcare Holdings at Seeking Alpha |
| 21-Jan-14 01:16PM | The 3 Most Intriguing Stories From the JPMorgan Healthcare Conference at Motley Fool |
| 07:55AM | Sarepta Therapeutics upgraded by Needham Briefing.com |
| 07:55AM | Sarepta Therapeutics upgraded by Needham |
| 07:23AM | Sarepta upgraded to Buy from Hold at Needham at theflyonthewall.com |
| 07:23AM | Sarepta upgraded to Buy from Hold at Needham |
| 18-Jan-14 07:54PM | JPMorgan Healthcare Conference Highlights: Sarepta Therapeutics at Motley Fool |
| 07:54PM | JPMorgan Healthcare Conference Highlights: Sarepta Therapeutics |
| 01:18PM | This Week in Biotech: Clinical Trials and Tribulations at Motley Fool |
| 09:36AM | The Best- And Worst-Performing Biotech Stocks, Jan. 10 to Jan. 17 at Forbes |
| 08:32AM | 3 Humongous Health-Care Stocks This Week at Motley Fool |
| 08:32AM | 3 Humongous Health-Care Stocks This Week |
| 17-Jan-14 01:50PM | My Five Favorite Bio-Pharma Stocks from the J.P. Morgan Healthcare Conference at TheStreet |
| 01:50PM | My Five Favorite Bio-Pharma Stocks from the J.P. Morgan Healthcare Conference |
| 01:42PM | A Big Day for Duchenne Muscular Dystrophy Drugmakers at Motley Fool |
| 01:42PM | A Big Day for Duchenne Muscular Dystrophy Drugmakers |
| 12:32AM | Sarepta Therapeutics (SRPT) Soars: Stock Up 40.1% Zacks |
| 12:32AM | Sarepta Therapeutics (SRPT) Soars: Stock Up 40.1% |
| 16-Jan-14 04:40PM | Why Sarepta Therapeutics, Rentrak, and Prosensa Are Today's 3 Best Stocks at Motley Fool +40.14% |
| 04:27PM | On The Fly: Closing Wrap at theflyonthewall.com |
| 03:10PM | Why Sarepta Therapeutics Inc. Shares Skyrocketed at Motley Fool |
| 12:33PM | On The Fly: Midday Wrap at theflyonthewall.com |
| 12:24PM | Sarepta climbs on new data for muscle drug AP |
| 12:24PM | Sarepta climbs on new data for muscle drug |
| 12:20PM | Midday movers: Twitter, Tyson, Rentrak & More at CNBC |
| 09:24AM | Why You Should Watch Amarin Corporation plc (ADR) and Sarepta Therapeutics Inc. Today at Motley Fool |
| 09:24AM | Why You Should Watch Amarin Corporation plc (ADR) and Sarepta Therapeutics Inc. Today |
| 15-Jan-14 11:31PM | Sarepta Therapeutics' CEO Presents at 32nd Annual J.P. Morgan Healthcare Conference (Transcript) at Seeking Alpha |
| 06:59PM | On The Fly: After Hours Movers at theflyonthewall.com |
| 05:58PM | Will Sarepta Therapeutics Benefit From GlaxoSmithKline's Exit? at Motley Fool |
| 05:55PM | Sarepta shares jump after hours on study results AP |
| 04:05PM | Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test through 120 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy Business Wire |
| 13-Jan-14 05:41PM | GSK Leaves Prosensa Hanging at Motley Fool |
| 05:41PM | GSK Leaves Prosensa Hanging |
| 04:12PM | It's Lunchtime at the J.P. Morgan Healthcare Confab. Here's What I Learned So Far at TheStreet |
| 04:12PM | It's Lunchtime at the J.P. Morgan Healthcare Confab. Here's What I Learned So Far |
| 11:34AM | Prosensa plummets after partnership with GSK terminated at theflyonthewall.com |
| 11:34AM | Prosensa plummets after partnership with GSK terminated |
| 09:34AM | Glaxo Drops Development of Prosensa's DMD Treatment at Bloomberg |
| 09:34AM | Glaxo Drops Development of Prosensa's DMD Treatment |
| 06:05AM | SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online |
| 06:05AM | SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure |
| 10-Jan-14 06:02AM | SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex EDGAR Online |
